Alendronate: An update of its use in osteoporosis

Drugs

Volumn 61, Issue 7, 2001, Pages 999-1039

  Sharpe, M ^a   Noble, S ^a   Spencer, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK FACTOR;

EID: 0034983101     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161070-00010     Document Type: Review

References (207)

1. Metabolic bone disease
2. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
3. Osteoporosis: Epidemiology, diagnosis, and treatment
4. Osteoporosis in men
5. The prevention and treatment of osteoporosis
6. Calcium, phosphorus, and bone metabolism: Calcium-regulating hormones
7. The prevention and treatment of osteoporosis
8. Treatment of postmenopausal osteoporosis
9. Treatment of patients with Paget's disease of bone
10. The management of Paget's disease of bone
11. Alendronate in the treatment of Paget's disease of bone
12. Alendronate in the treatment of Paget's disease of bone
13. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats
14. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats
15. Comparative tolerability of drug therapies for hypercalcaemia of malignancy
16. The effect of alendronate on bone mass after distal forearm fracture
17. Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
18. Cellular and molecular mechanisms of action of bisphosphonates
19. Bisphosphonates: From the laboratory to the clinic and back again
20. Alendronate: Preclinical studies
21. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
22. 3H-etidronate in rat and mouse bones
23. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat
24. Human osteoclast formation and activity in vitro: Effects of alendronate
25. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy
26. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
27. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells
28. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
29. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
30. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
31. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mstl kinase during apoptosis: A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
32. Farnesol and geranyl-geraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
33. Alendronate is a specific, nanomolar inhibitor of famesyl diphosphate synthase
34. Mechanism of aminobisphosphonate action: Characterization of alendronate inhibition of the isoprenoid pathway
35. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate
36. Alendronate inhibition of protein-tyrosine-phosphatase-megl
37. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
38. Alendronate for treatment of osteoporosis in elderly female long term care facility residents: Effect on biochemical markers of bone turnover
39. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
40. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis
41. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
42. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate
43. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial
44. Alendronate for the treatment of osteoporosis in men
45. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
46. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, doubleblind, placebo-controlled extension trial
47. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women
48. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the Early Postmenopausal Intervention Cohort Study: A randomized, controlled trial
49. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: Two years of continuous treatment
50. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis
51. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women
52. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
53. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
54. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study
55. Effects of raloxifene (RLX), alendronate (ALN) and RLX + ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis
56. Short-term variations in bone remodeling biochemical markers: Cyclical etidronate and alendronate effects compared
57. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae
58. Alendronate and calcium for treatment of osteoporosis in postmenopausal women: Effect on biochemical markers of bone turnover
59. Comparative effects of calcium and calcium + vitamin D on the biochemical markers of bone remodeling in osteoporotic and osteopenic postmenopausal women treated with alendronate
60. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
61. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: A histomorphometric analysis of transiliac biopsies
62. Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications
63. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
64. Dose-response relationships for alendronate treatment in osteoporotic elderly women
65. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs
66. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae
67. Effect of alendronate on fracture healing and bone remodeling in dogs
68. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomised nonhuman primates
69. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats
70. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties
71. Supressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
72. Upper gastrointestinal toxicity of alendronate
73. Alendronate gastric ulcers
74. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women
75. Effects of alendronate on gastric and duodenal mucosa
76. Oral alendronate 70 mg once weekly is not associated with endoscopic upper GI mucosal lesions compared to placebo
77. Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate
78. The effects of amino-versus alkylbisphosphonates on the healing of aspirin-induced stomach erosions in healthy subjects
79. Esophageal irritation due to alendronate sodium tablets: Possible mechanisms
80. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation
81. Pharmacokinetics of alendronate
82. Studies of the oral bioavailability of alendronate
83. Pharmacokinetics of intravenous alendronate
84. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
85. Oral bioavailability of alendronate 35- and 70-mg tablets
86. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals
87. Note for guidance on postmenopausal osteoporosis in women
88. Recommmendations for the registration of new clinical entities used in the prevention and treatment of osteoporosis
89. Bone density at various sites for prediction of hip fractures
90. Long-term fracture prediction by bone mineral assessed at different skeletal sites
91. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
92. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
93. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report
94. What constitutes evidence for drug efficacy in osteoporosis?
95. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis
96. The crippling consequences of fractures and their impact on quality of life
97. Decline in physical function following hip fracture
98. Mortality after all major types of osteoporotic fracture in men and women: An observational study
99. Clinical consequences of vertebral fractures
100. Guidelines for diagnosis and management of osteoporosis
101. Treatment of postmenopausal osteoporosis with alendronate and MK-677 (a growth hormone secretagogue) individually and in combination
102. Alendronate prevents bone loss in Chinese women with osteoporosis
103. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study
104. Alendronate for treatment of osteoporosis in elderly female long term care facility (LTCF) residents
105. A randomized, parallel group study comparing the efficacy of continuous versus cyclic alendronate in the treatment of postmenopausal women with low bone mass
106. Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis
107. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures
108. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
109. Effect of treatment with calcitriol combined with low-dosage alendronate in involutional osteoporosis
110. Therapeutic equivalence of alendronate (ALN) 35-mg once weekly (OW) and 5-mg daily (D) in the prevention of postmenopausal osteoporosis
111. Effect of alendronate sodium on bone mineral density in postmenopausal, osteoporotic Black women of African-American descent
112. Oral alendronate induces progressive increases in bone mass of the spine, hip and total body over three years in postmenopausal women with osteoporosis
113. Alendronate reverses the bone loss associated with discontinuation of hormone replacement therapy
114. Response to alendronate following cyclical etidronate therapy in osteoporotic patients
115. Once-weekly alendronate: Subgroup efficacy analyses
116. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis
117. Alendronate vs. calcium for treatment of osteoporosis in postmenopausal women
118. Treatment of osteoporosis in postmenopausal women: Alendronate vs. intranasal calcitonin
119. Prevention of corticosteroid-induced bone loss with alendronate
120. Differential effects of alendronate and estrogen on the rate of bone loss after discontinuation of treatment
121. Effects of combined estrogen and alendronate treatments in osteoporotic women
122. Efficacy of alendronate with and without hormone replacement therapy (HRT) on spinal bone density in 74 postmenopausal, osteopenic women
123. Efficacy of alendronate with and without hormone replacement therapy (HRT) on femoral bone density in 74 postmenopausal, osteopenic women
124. Efficacy of alendronate with and without hormone replacement therapy (HRT) on forearm bone density in 74 postmenopausal, osteopenic women
125. Calcitriol and alendronate combination treatment in menopausal women with low bone mass
126. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
127. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
128. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
129. Prevalence of low femoral bone density in older U.S. women from NHANES III
130. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: Effect of number and spinal location of fractures
131. Alendronate reduces the risk of multiple clinical fractures: Results from FIT
132. Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trial
133. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures
134. The effect of alendronate on disability days due to fracture: A new integrated measure of the effect of treatments for osteoporosis
135. Consistency of effect of alendronate on reduction in risk of hip fractures
136. Consistency of effect of alendronate on reduction in risk of non-vertebral fractures
137. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups
138. Long-term prevention of postmenopausal bone loss with alendronate. Effects of continuous treatment and after withdrawal
139. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
140. Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal
141. Effects of baseline bone mineral density on response to treatment with alendronate for four years
142. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women
143. Effects of alendronate on osteopenic postmenopausal Chinese women
144. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: Data from FIT
145. Alendronate treatment in men with primary osteoporosis: A 3-year longitudinal study
146. Prevalence of low femoral bone density in older U.S. adults from NHANES III
147. Male osteoporosis therapy: The impact of 12 months alendronate sodium on the BMD at the lumbar spine, at the hip and at the forearm
148. Treatment of established primary osteoporosis in men with alendronate or alfacalcidol
149. Effectiveness of etidronate and alendronate in the treatment of osteoporosis in males: A prospective observational study
150. Do disease and concomitant medications influence the effect of alendronate on spine BMD in patients receiving glucocorticoids?
151. Alendronate increases bone mineral density in men receiving glucocorticoids
152. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients
153. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
154. The effects of oral alendronate on bone mass and turnover and safety: Five-year treatment of osteoporosis in postmenopausal women
155. Upper gastrointestinal tract safety profile of alendronate: The fracture intervention trial
156. Safety and tolerability of once-weekly alendronate 70 mg is comparable to that of placebo in men and women with periodontal disease
157. Upper gastrointestinal ulceration with alendronate
158. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms
159. Esophagatis associated with the use of alendronate
160. United Kingdom experience with alendronate and oesophageal reactions
161. Incidence of adverse oesophageal and gastric events in alendronate users
162. Esophageal stricture associated with alendronate therapy
163. A new probable increasing cause of esophageal ulceration: Alendronate
164. Alendronate-associated esophagitis: Endoscopic and pathologic features
165. Esophagitis associated with the use of alendronate. Report of two cases
166. Severe oral ulcerations induced by alendronate
167. Alendronate in the treatment of osteoporosis: A review of the clinical trials
168. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
169. Esophagitis dissecans superficialis and alendronate: Case report
170. Alendronate-induced esophagitis: Case report of a recently recognized form of severe esophagitis with esophageal stricture-radiographic features
171. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation
172. A Bayesian analysis of bisphosphonate effects and cost-effectiveness in post-menopausal osteoporosis
173. A cost-effectiveness analysis of calcium and vitamin D vs alendronate in the prevention of corticosteroid-induced osteoporosis
174. The cost-effectiveness of alendronate in the prevention of osteoporotic fractures in elderly women
175. Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures
176. Cost-effectiveness of pharmaceutical interventions in postmenopausal women: A comparison of raloxifene, hormone replacement therapy, and alendronate
177. Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES)
178. Who are candidates for prevention and treatment for osteoporosis?
179. Perspective: How many women have osteoporosis?
180. AUK Consensus Group on management of glucocorticoid-induced osteoporosis: An update
181. Diagnosis and treatment of glucocorticoid-induced osteoporosis
182. Management of established osteoporosis
183. Osteoporosis prevention and treatment
184. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
185. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
186. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
187. Effect of risedronate on the risk of hip fracture in elderly women
188. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
189. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines
190. Raloxifene: A review of its use in postmenopausal osteoporosis
191. Management of male osteoporosis: Report of the UK Consensus Group
192. Osteoporosis in men
193. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease
194. Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients?
195. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss
196. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
197. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
198. Use of oral corticosteroids and risk of fractures